BRITISH JOURNAL OF PHARMACOLOGY;
Br. J. Pharmacol.

dc.creatorHANCKE-OROZCO, JUAN
dc.creatorBURGOS-AGUILERA, RAFAEL
dc.creatorCONCHA-GRABINGER, ILONA
dc.creatorCORTES, PATRICIA
dc.creatorFIGUEROA, JAIME
dc.creatorHIDALGO-GOMEZ, MARIA
dc.creatorROMERO-ZUÑIGA, ALEX
dc.date2017-04-27T18:52:31Z
dc.date2022-07-07T02:24:03Z
dc.date2017-04-27T18:52:31Z
dc.date2022-07-07T02:24:03Z
dc.date2005
dc.date.accessioned2023-08-22T02:20:40Z
dc.date.available2023-08-22T02:20:40Z
dc.identifier0
dc.identifierD01I1024
dc.identifierD01I1024
dc.identifierWOS:000227828000009
dc.identifier0007-1188
dc.identifierhttps://hdl.handle.net/10533/197685
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8310132
dc.description1 Andrographolide, the major active component from Andrographis paniculata, has shown to possess anti-inflammatory activity. Andrographolide inhibits the expression of several proinflammatory proteins that exhibit a nuclear factor kappa B (NF-kappa B) binding site in their gene. 2 In the present study, we analyzed the effect of andrographolide on the activation of NF-kappa B induced by platelet-activating factor (PAF) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) in HL-60 cells differentiated to neutrophils. 3 PAF (100 nM) and fMLP (100 nM) induced activation of NF-kappa B as determined by degradation of inhibitory factor B alpha (I kappa B alpha) using Western blotting in cytosolic extracts and by binding to DNA using electrophoretic mobility shift assay (EMSA) in nuclear extracts. 4 Andrographolide (5 and 50 mu M) inhibited the NF-kappa B-luciferase activity induced by PAF. However, andrographolide did not reduce phosphorylation of p38 MAPK or ERK1/2 and did not change IkBa degradation induced by PAF and fMLP. 5 Andrographolide reduced the DNA binding of NF-kappa B in whole cells and in nuclear extracts induced by PAF and fMLP. 6 Andrographolide reduced cyclooxygenase-2 (COX-2) expression induced by PAF and fMLP in HL-60/neutrophils. 7 It is concluded that andrographolide exerts its anti-inflammatory effects by inhibiting NF-kappa B binding to DNA, and thus reducing the expression of proinflammatory proteins, such as COX-2.
dc.description0
dc.description80
dc.descriptionFONDEF
dc.descriptionrburgos1@uach.cl
dc.description0
dc.descriptionFONDEF
dc.description144
dc.languageENG
dc.publisherWILEY-BLACKWELL
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.relationinfo:eu-repo/grantAgreement/Fondef/D01I1024
dc.relationinfo:eu-repo/semantics/dataset/hdl.handle.net/10533/93477
dc.relationhttps://doi.org/10.1038/sj.bjp.0706105
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleAndrographolide interferes with binding of nuclear factor-kb to dna in hl-60-derived neutrophilic cells
dc.titleBRITISH JOURNAL OF PHARMACOLOGY
dc.titleBr. J. Pharmacol.
dc.typeArticulo
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.coverageHOBOKEN


Este ítem pertenece a la siguiente institución